SCHEMBL3256154

SCHEMBL3256154

Cc1cc(Cl)cc(Cl)c1S(=O)(=O)Nc1ncc(CC(=O)N2CCCCC2)s1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 5/20 0.55
HPGD P15428 4/20 0.39
TSHR P16473 4/20 0.39
NPC1 O15118 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 2/20 0.39
RAB9A P51151 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CCNC P24863 1/20 0.36
CDK8 P49336 1/20 0.36
HSD17B1 P14061 1/20 0.35
HSD17B2 P37059 1/20 0.35
GAA P10253 1/20 0.35
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3250317 0.92 HSD11B1 (0.66) HSD11B1HPGDLMNAMEN1KMT2A
SCHEMBL3254353 0.92 HSD11B1 (0.60) HSD11B1TSHRSMN1; SMN2LMNARAB9A
SCHEMBL3255541 0.92 HSD11B1 (0.54) HSD11B1LMNAKMT2ACCNCCDK8
SCHEMBL3258283 0.84 HSD11B1 (0.43) HSD11B1TSHRLMNAMEN1KMT2A
SCHEMBL5831036 0.84 CCNC (0.52) HSD11B1HPGDTSHRNPC1SMN1; SMN2
SCHEMBL6627313 0.83 HSD11B1 (0.42) HSD11B1HPGDTSHRMEN1KMT2A
SCHEMBL5830658 0.82 HSD11B1 (0.50) HSD11B1HPGDTSHRNPC1SMN1; SMN2
SCHEMBL3613128 0.81 HSD11B1 (0.72) HSD11B1MEN1KMT2AHSD17B1HSD17B2
SCHEMBL3248368 0.80 HSD11B1 (0.41) HSD11B1TSHRSMN1; SMN2LMNAMEN1
SCHEMBL3252155 0.80 HSD11B1 (0.41) HSD11B1HPGDLMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1461325-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-05-26 EP claimed
US-7671051-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2010-03-02 US claimed
US-20050250776-A1 Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 BIOVITRUM AB 2005-11-10 US claimed
WO-2004112782-A1 NEW USE V BIOVITRUM AB (SE) 2004-12-29 WO claimed
US-20030130318-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US claimed
EP-1461325-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-05-26 EP disclosed
US-7671051-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2010-03-02 US disclosed
US-7094792-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-08-22 US disclosed
US-20050250776-A1 Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 BIOVITRUM AB 2005-11-10 US disclosed
WO-2004112782-A1 NEW USE V BIOVITRUM AB (SE) 2004-12-29 WO disclosed
US-20030130318-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250776-A1 Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 HSD11B1, HSD17B1, HSD17B11 HSD11B1 1/4885HPGD 105/4885TSHR 1374/4885
US-20030130318-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 HSD11B1 1/4885HPGD 51/4885TSHR 4127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.